A specialized team. A tailored approach.

Your work brings hope to the families of over 350 million people living with one of 7,000 rare diseases. With so few approved treatments, you can make a real difference. But you face immense challenges in finding dispersed patients, identifying meaningful endpoints, creating novel study designs and executing everything flawlessly.

And a pre-fabricated solution won’t do. Each product, each project requires special, tailored attention to make sure the right questions are asked, and the right team is in place to answers.

Backed by the exceptional approach and resources of IQVIA, the leading human data science company, our unified team of experts is ready to help:

  • Speed recruitment by quickly and confidently identifying the right early-stage patients with our proprietary algorithms and real-world data.
  • Help reduce costs through our Rare Disease Magnet Sites and relationships with appropriate medical centers worldwide.
  • Collaborate with clinical experts who’ve been there and delivered. Our Rare Disease Center of Excellence helps you design and oversee complex studies and protocols, provide experienced regulatory counsel, and advance your treatment toward rapid approval and reimbursement.
  • Improve commercial decisions with our leading advanced analytics, machine learning and predictive analytics capabilities.
  • Understand the impact of new innovations and treatments, including regenerative medicines, cell and gene therapy, and a new generation of biosimilars

Accelerate your fight against rare disease with unparalleled data; insightful and actionable analytics; advanced technology; and unrivaled institutional knowledge.

Let us help you develop and deliver your rare disease treatment successfully.

Flexible solutions for Emerging Biopharma Companies
From defining the plan for your asset, to trial implementation, through launch and commercialization, IQVIA can help you find your path to success.
IQVIA Cell and Gene Therapy Center
Strategic and operational services, complemented by a comprehensive network of partners to address unique challenges in advanced therapies.